Clinical Trial

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Study acronym: DURGA-3
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2026 (before its estimated March 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-01-23; most recent amendment 2026-02-24.
Trial Details
NCT Number NCT06235229
Lead Sponsor Gracell Biotechnologies (Shanghai) Co., Ltd.
Conditions Multiple Myeloma
Enrollment 110 participants
Start Date 2023-12-26
Primary Completion 2026-03-02 (estimated)
Study Completion 2026-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-25